Capstone Partners served as exclusive financial advisor to founder-owned Time-Cap Labs, Inc. in its sale to Marksans Pharma Limited.
Time-Cap, established in 1978, is a leading manufacturer of solid dose pharmaceuticals, including private label over-the-counter (OTC) medications, generic prescription (Rx) drugs and nutritional supplements.
Time-Cap possesses differentiated manufacturing capabilities with competitive advantages in extended and delayed-release products and specialized coating expertise.
Marksans Pharma Limited (BSE:524404), headquartered in Mumbai, India, manufactures and markets generic OTC pharmaceuticals globally and has a market cap of over $550 million.
The strategic acquisition of Time-Cap provides Marksans with its first manufacturing facility in the U.S., an expanded product portfolio and capabilities to pursue ANDAs for high margin products.
Selling a business you started and have grown over four decades represents the realization of your life’s work, and our advisors at [Capstone Partners] clearly understood the importance of this transaction to the Errigo family. [Capstone Partners] deep industry knowledge, global reach, trusted advice and extraordinary perseverance were keys to generating a superior outcome – and we feel incredibly lucky to have had them by our side throughout this process.
